Viking Therapeutics Inc.
Developing “undervalued” assets for metabolic, endocrine disorders
This article was originally published in Start Up
Viking Therapeutics Inc. has clinical-stage compounds for disorders amplifying as the world's population ages. The start-up’s first drug candidate is a potential treatment for people recovering from hip fracture; the second shows promise for fatty liver disorders that are spreading as the western diet does.